244 related articles for article (PubMed ID: 30027791)
61. Cinacalcet for managing secondary hyperparathyroidism in dialysis patients in clinical practice in Belgium: a 16-month observational study (ECHO-B).
Debelle F; Meeus G; Dratwa M; Maes B; Vanholder R; Albert A; Schutyser E; Jadoul M
Acta Clin Belg; 2013; 68(4):275-81. PubMed ID: 24455797
[TBL] [Abstract][Full Text] [Related]
62. [Secondary hyperparathyroidism and anemia. Effects of a calcimimetic on the control of anemia in chronic hemodialysed patients. Pilot Study].
Mpio I; Boumendjel N; Karaaslan H; Arkouche W; Lenz A; Cardozo C; Cardozo J; Pastural-Thaunat M; Fouque D; Silou J; Attaf D; Laville M
Nephrol Ther; 2011 Jul; 7(4):229-36. PubMed ID: 21353659
[TBL] [Abstract][Full Text] [Related]
63. [Long-term efficacy and safety of etelcalcetide in hemodialysis patients with severe secondary hyperparathyroidism].
Massimetti C; Tondo M; Feriozzi S
G Ital Nefrol; 2020 Oct; 37(5):. PubMed ID: 33026204
[No Abstract] [Full Text] [Related]
64. Treatment of secondary hyperparathyroidism: the clinical utility of etelcalcetide.
Cozzolino M; Galassi A; Conte F; Mangano M; Di Lullo L; Bellasi A
Ther Clin Risk Manag; 2017; 13():679-689. PubMed ID: 28615947
[TBL] [Abstract][Full Text] [Related]
65. Frequent monitoring of mineral metabolism in hemodialysis patients with secondary hyperparathyroidism: associations with achievement of treatment goals and with adjustments in therapy.
Yokoyama K; Kurita N; Fukuma S; Akizawa T; Fukagawa M; Onishi Y; Kurokawa K; Fukuhara S
Nephrol Dial Transplant; 2017 Mar; 32(3):534-541. PubMed ID: 26945054
[TBL] [Abstract][Full Text] [Related]
66. Etelcalcetide in Patients on Hemodialysis with Severe Secondary Hyperparathyroidism. Multicenter Study in "Real Life".
Russo D; Tripepi R; Malberti F; Di Iorio B; Scognamiglio B; Di Lullo L; Paduano IG; Tripepi GL; Panuccio VA
J Clin Med; 2019 Jul; 8(7):. PubMed ID: 31330805
[TBL] [Abstract][Full Text] [Related]
67. Population Pharmacokinetics and Pharmacodynamics of the Calcimimetic Etelcalcetide in Chronic Kidney Disease and Secondary Hyperparathyroidism Receiving Hemodialysis.
Chen P; Olsson Gisleskog P; Perez-Ruixo JJ; Xiao J; Wilkins J; Narayanan A; Gibbs JP; Melhem M
CPT Pharmacometrics Syst Pharmacol; 2016 Sep; 5(9):484-94. PubMed ID: 27639083
[TBL] [Abstract][Full Text] [Related]
68. [The influence of side effects related to cinacalcet therapy on compliance in hemodialysis patients suffering from secondary hyperparathyroidism].
Zwiech R; Chrul S
Wiad Lek; 2012; 65(3):145-50. PubMed ID: 23289260
[TBL] [Abstract][Full Text] [Related]
69. The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidism.
Lindberg JS; Moe SM; Goodman WG; Coburn JW; Sprague SM; Liu W; Blaisdell PW; Brenner RM; Turner SA; Martin KJ
Kidney Int; 2003 Jan; 63(1):248-54. PubMed ID: 12472790
[TBL] [Abstract][Full Text] [Related]
70. Administration of calcimimetics after dialysis: same effectiveness, better gastrointestinal tolerability.
Esteve Simo V; Moreno-Guzmán F; Martínez Calvo G; Fulquet Nicolas M; Pou Potau M; Macias-Toro J; Duarte-Gallego V; Saurina Sole A; Ramírez-de Arellano Serna M
Nefrologia; 2015; 35(4):403-9. PubMed ID: 26306967
[TBL] [Abstract][Full Text] [Related]
71. Managing hyperparathyroidism in hemodialysis: role of etelcalcetide.
Eidman KE; Wetmore JB
Int J Nephrol Renovasc Dis; 2018; 11():69-80. PubMed ID: 29440923
[TBL] [Abstract][Full Text] [Related]
72. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients.
Strippoli GF; Tong A; Palmer SC; Elder G; Craig JC
Cochrane Database Syst Rev; 2006 Oct; (4):CD006254. PubMed ID: 17054287
[TBL] [Abstract][Full Text] [Related]
73. Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism.
Ruderman I; Smith ER; Toussaint ND; Hewitson TD; Holt SG
BMC Nephrol; 2018 May; 19(1):113. PubMed ID: 29764395
[TBL] [Abstract][Full Text] [Related]
74. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Liu Y; Yang Q; Chen G; Zhou T
Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
[TBL] [Abstract][Full Text] [Related]
75. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study.
Cozzolino M; Ketteler M; Martin KJ; Sharma A; Goldsmith D; Khan S
Nephrol Dial Transplant; 2014 Apr; 29(4):899-905. PubMed ID: 24500308
[TBL] [Abstract][Full Text] [Related]
76. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.
Stollenwerk B; Iannazzo S; Akehurst R; Adena M; Briggs A; Dehmel B; Parfrey P; Belozeroff V
Pharmacoeconomics; 2018 May; 36(5):603-612. PubMed ID: 29392552
[TBL] [Abstract][Full Text] [Related]
77. Comparative Effects of Etelcalcetide and Maxacalcitol on Serum Calcification Propensity in Secondary Hyperparathyroidism: A Randomized Clinical Trial.
Shoji T; Nakatani S; Kabata D; Mori K; Shintani A; Yoshida H; Takahashi K; Ota K; Fujii H; Ueda S; Nishi S; Nakatani T; Yoshiyama M; Goto K; Hamada T; Imanishi M; Ishimura E; Kagitani S; Kato Y; Kumeda Y; Maekawa K; Matsumura T; Nagayama H; Obi Y; Ohno Y; Sai Y; Sakurai M; Sasaki S; Shidara K; Shoji S; Tsujimoto Y; Yamakawa K; Yasuda H; Yodoi S; Inaba M; Emoto M
Clin J Am Soc Nephrol; 2021 Apr; 16(4):599-612. PubMed ID: 33685864
[TBL] [Abstract][Full Text] [Related]
78. EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice.
Hemetsberger M; Oberbauer R; Erb H; Pronai W
Wien Med Wochenschr; 2015 Oct; 165(19-20):410-8. PubMed ID: 26302869
[TBL] [Abstract][Full Text] [Related]
79. Survival after parathyroidectomy in chronic hemodialysis patients with severe secondary hyperparathyroidism.
Moldovan D; Racasan S; Kacso IM; Rusu C; Potra A; Bondor C; Patiu IM; Gherman-Căprioară M
Int Urol Nephrol; 2015 Nov; 47(11):1871-7. PubMed ID: 26377492
[TBL] [Abstract][Full Text] [Related]
80. Nonclinical Safety Profile of Etelcalcetide, a Novel Peptide Calcimimetic for the Treatment of Secondary Hyperparathyroidism.
Fielden MR; Dean C; Black K; Sawant SG; Subramanian R; Tomlinson JE; Walter S; Zimmermann C; Griggs MW; McKeon ME; Lewis EM; Beevers C; Pyrah I
Int J Toxicol; 2016 May; 35(3):294-308. PubMed ID: 26941242
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
